News

TPN171H, an experimental oral therapy for pulmonary arterial hypertension (PAH), was generally safe and showed a favorable pharmacological profile in healthy volunteers, according to data from a Phase 1 clinical trial. The therapy — previously reported to be a more potent and selective PDE5 suppressor than sildenafil in…

A protein known as cell division cycle protein 2 (CDC2) enhances the proliferation of pulmonary artery smooth muscle cells — those lining the walls of lung arteries — in people with pulmonary arterial hypertension (PAH), a study reported. Additionally, the increased level of CDC2 in these cells was found…

The PAPi blood pressure test was able to accurately predict mortality in Asian people with pulmonary arterial hypertension (PAH), a 14-year study revealed. Despite that finding, the multi-factor REVEAL score was found to still be the best predictor for mortality risk in PAH. “In our analysis, low PAPi was…

Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…

U.S. veterans infected with the human immunodeficiency virus (HIV) — the virus that causes AIDS — are at higher risk of pulmonary hypertension (PH), according to a large study in this population. “HIV infection had a direct effect on incident pulmonary hypertension among US veterans,” including those with no history…

Non-alcoholic fatty liver disease (NAFLD) — an umbrella term for conditions caused by a buildup of fat in the liver — is about twice as common among people who have pulmonary hypertension (PH) than among those who do not, a review of almost 19,000 people has shown. The finding…

The likelihood of developing pulmonary hypertension (PH) is low among people in southern Italy, suggests a study that draws from a random and large grouping of individuals with echocardiograms, done to determine disease prevalence. Independent predictors of PH include female sex and right ventricular enlargement, its scientists noted. The study,…

People with stable pulmonary arterial hypertension (PAH) can safely switch from Tracleer (bosentan) to Letairis (ambrisentan) without compromising their heart function or general health status, a study from China reports. PAH patients in Hunan province may also benefit financially by moving from Tracleer to Letairis, as it…

At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases within the next decade. A leader in the field of genetic diagnostics, Centogene used the June 22 event to present its strategic priorities, outlining its plans to speed the discovery…

Joining support groups — meeting people with common experiences and concerns who can provide emotional reassurance — for pulmonary hypertension (PH) helped patients manage symptoms, stick to medicines, and better understand their disease, a study reports. Participation in a support group, however, had no impact on the general quality…

A study of rare gene variants has identified two new candidates — fibulin 2 (FBLN2) and platelet-derived growth factor D (PDGFD) — that increase risk for adult-onset idiopathic pulmonary arterial hypertension (IPAH). In-depth genetic analyses also predicted that about 15% of IPAH cases in children are caused by de…

Dosing has begun in a clinical trial testing AER-901, Aerami Therapeutics‘ inhaled formulation of imatinib, which is being investigated as a potential treatment for pulmonary arterial hypertension (PAH). “We are pleased to announce that the dosing of subjects in our Phase 1 trial is ongoing and that we expect to…